



## Supplementary figure 1



## Supplementary figure 1

The figure shows the immuno-reactivity of individual peptides (P3, P9, P11) of wild type of SARS-CoV-2 and individuals' peptides (P4, P10, P12) of SARS-CoV-2 variants with anti-sera obtained from individuals vaccinated with both doses of Covishield (n=30) and COVID-19 recovered patients from the hospital (n=30). **Fig.1S A** shows the immuno-reactivity of anti-sera with a peptide sequence P3 (wild) and P4 (mutant) having mutations at two amino acid residues at position 477 and 478. **Fig.1S B** shows the immuno-reactivity of anti-sera with a peptide sequence P9 (wild) and P10 (mutant) having mutations at two amino acid residues at position 400 and 446. **Fig.1S C** shows the immuno-reactivity of anti-sera with a peptide sequence P11 (wild) and P12 (mutant) having five mutations at amino acid residues at position 493,496,498,501, and 505.



**Supplementary Fig.1S:** The figure shows the immuno-reactivity of individual peptides (P3, P9, P11) of wild type of SARS-CoV-2 and individuals peptides (P4, P10, P12) of SARS-CoV-2 variants with anti-sera obtained from individuals vaccinated with both doses of Covishield (n=30) and COVID-19 recovered patients from the hospital (n=30). **Fig.1S A** shows the immuno-reactivity of anti-sera with a peptide sequence P3 (wild) and P4 (mutant) having mutations at two amino acid residues at position 477 and 478. **Fig.1S B** shows the immuno-reactivity of anti-sera with a peptide sequence P9 (wild) and P10 (mutant) having mutations at two amino acid residues at position 400 and 446. **Fig.1S C** shows the immuno-reactivity of anti-sera with a peptide sequence P11 (wild) and P12 (mutant) having five mutations at amino acid residues at position 493,496,498,501, and 505.